Recent Advances in Peptide Linkers for Antibody-Drug Conjugates: Building Smarter ADCs for Precision Cancer Therapy
Antibody-drug conjugates (ADCs) have become one of the most important therapeutic platforms in modern oncology. By combining the high target specificity of monoclonal antibodies with the strong cytotoxic activity of small-molecule payloads, ADCs offer a way to deliver potent drugs directly to cancer cells while reducing systemic exposure. This “targeted delivery” concept has transformed the […]
LinkPeptide